Member Info for sadoldgit

Hood, you are getting desperate sonny!

More utter garbage from you.

It’s a heavily discounted placing or a one in a million shot of some kind of non-dilutive funding like a licensing deal. The Holy Grail for small cap pharmas that never actually happens in real-life, especially to companies who don’t have any efficacy data.

Take a look at CCT245737 compound that was licenced a while ago.that was in phase1 clinical trial being of safety profile only. No clinical efficacy results as phase 1.

Upfront payment was smallish but total including milestone payments was circa 300 million.

So they do happen and not once in a million probability

Regards

Good afternoon Carter19.

The Hood asks questions and makes out he is clever, cunning yes, but not clever.

ADVN share chat very amusing.

Poor Robin is being bullied.

Stays in a box room at his mums or similar.

That bullying talk?

Very similar overtones to that circle of life deviant that was scaremongering about nitrosamines a while back. It don't post here anymore.

I have posted 5 times at night so must be worried about my investment in Sareum.

Jeez you have to laugh.

I post at night when l get called onto work.

At times the work does not go ahead so l am stuck in my off site cabin with a pager.

Trust all is well with you.

Regards

Regards

Hood

You really ate an odd ball.

Note carefully below the reply l received from Sareum

Read and try to understand

'Thank you for your email and interest in supporting Sareum, which is much appreciated.

As noted in our RNS of March 12, we are currently assessing funding sources. Should we pursue an equity fundraise, as we have done before we would anticipate giving existing shareholders the opportunity to participate. As we have done in the past, we would expect this would be through one of the retail platforms such as Wrap or Bookbuild. If this is the case, then full details will be announced to the market, and we will ensure that in addition we send you a copy of that announcement.'

With best regards, Sareum IR'

'We are assessing funding sources,'

'Should we pursue an equity fundraise'

From what is written above Sareum have more than one option of how to raise funds.

First part of phase 1 ie phase 1 completed with expected top line results.

That from dualified people a bit further up the knowledge tree than you are likely to ever reach.

You know nothing of the company and nothing about the biotech business.

You post nothing of substance just the same old childish drivel.

I remember the Puma posting.

Sareum will have the option to onlicence on phase1a data alone or raise funds to progress to phase1b

At phase 1a value less with smaller upfront payment. Phase 1b higher value larger upfront payment.

Most likely out come will be an on license during phase 1b trials in my honest opinion.

Sareum will overcome this problem irrespective of what ever you post here.

Your only interest is the SP falling.

You spout absolute unsubstantiated rubbish to push your agenda.

Have a good day and your time frame with regards of your short working are rapidly coming to an end.

S

Post below relating to Aurora +FLT3

https://pubmed.ncbi.nlm.nih.gov/34446858/

Although it does not mention Sareum l am pretty sure it is the Sareum compound.

Why would l think that?

CCT245738. First numbers relate to heterocyclic rings and molecule structure.

There was no advancement in this as halted by solubility issues for sufficient amounts if the compound to be taken intravenously.

An option would be via the oral route.

Unfortunately to continue development of SDC-1801 funds were diverted away from progress of

Aurora FLT3.

Nothing of any significance here regarding future funding, it is shelved until we are notified otherwise.

Https://www.factmr.com/report/immune-checkpoint-inhibitor-market#:~:text=Immune%20Checkpoint%20Inhibitor%20Market%20Outlook,14.7%25%20from%202024%20to%202034.

Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671062/#:~:text=LATTICE%2DUC%20was%20a%20double,more%20conventional%20or%20biologic%20therapies.

Hood,

'It’s probably not enough, realistically. You really want it to get you to the end of Ph1b. How long is that going to take? 2-3 years at least at the pace these guys typically operate, I’d say.'

What a load of tosh you post here.

Plan is to complete phase1b at end of 2024. This is notified to us numerous times via RNS'S. These statements have far more credibility than any of your ill conceived opinions.

One reason that Sareum would have used this facility is to prove that they have the ability to access finance to fund the stage1 trial.

This is a requirement of a CTA application. Without this access to funding the CTA application would never have been granted.

The first part ie 1a of the trial is basically complete and awaiting final detailed results that will enable from the point of view of satisfactory safety results to enter into phase1b.

With regards to finance our development of SDC1801 we are at later stage than end of preclinical. Top line results are expected as stated in Sareums RNS.

I would certainly take this having credibility over the complete and utter ill conceived drivel that you post here.

As for the 4 million required you make no sense.

You have stated when asked previously why a figure of 4 million and what will it be spent on and you ludicrously reply with directors salaries.

Sareum are working at seeking an alternative form of financing. This in reality should present no real problems on conclusion of 1a safety data along with biomarker data.

I am sure you understand the importance and knock on effect for this data not only for 1801 but also 1802.

If you cannot comprehend this or more likely refuse to acknowledge this fact then tt is evident that your knowledge and understanding of drug discovery, preclinical development, CTA application, phase1,2 and 3 stages of success with corresponding increase in value at each stage are at best very poor.

Regards.

Reality10, l would like to think that the BoD do visit this BB and dramatically change their attitude and communicate to us in such a way that they take on constructive criticism and address these issues, signalling to us that we are not investors that are bring taken for granted.

Surely that is in no way being unreasonable.

Regards

Reality10, you had an opportunity to sit down in front of the board at the AGM. Why didn't you attend the AGM and vent your views then?

Regards

Hood

Why do they have to raise several million quid?

Regards

The Hood

' The problem, if you don’t raise enough, is that everyone knows there needs to be a further raise. They have to raise several million quid this time round else there’s no point.'

In what capacity are you to state '

'They have to raise several million quid this time round else there’s no point.'

Regards

The Hood, why does there need to be a furthere raise. This ' everybody knows' can you tell us who this everybody is? Do you know who they are?

Regards

That would makes sense rioutd777.

Not overly sure if they could issue new shares, but then again that is what they have been doing with Riverfort.

Regards

Good morning PCS1954

Yes, sareum indeed need to release comprehensive detail. That will be a first for them.

Although a tad different to us, an interesting deal below for BMS.

https://news.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-Completes-Acquisition-of-RayzeBio-Adding-Differentiated-Actinium-Based-Radiopharmaceutical-Platform/default.aspx#:~:text=Based%20Radiopharmaceutical%20Platform-,Bristol%20Myers%20Squibb%20Completes%20Acquisition%20of%20RayzeBio,Differentiated%20Actinium%2DBased%20Radiopharmaceutical%20Platform&text=Category%3A&text=PRINCETON%2C%20N.J.%2D%2D(BUSINESS%20WIRE,its%20acquisition%20of%20RayzeBio%2C%20Inc.

Regards

With regards to raising finance.

Try getting a mortgage or loan on a property and what is required is a market valuation. The data from this valuation will allow within banking practices a percentage of loan that they will lend.

No valuation no mortgage.

That is an extremely simplified analogy of where Sareum sit.

Had our market cap stayed above the 2 pounds a share mark and not been hammered by the return of 737 to CPF or the MHRA being inept with inexperienced staff with consequently being unable to grant approval at what SP would you put on Sareum with the considerable progress and early phase1 a data results?

Has the price prepared to be paid for a potential best in class autoimmune inhibitor dropped?

Maybe a tad yes but nowhere near the amount to justify going from 150 million to a 15 million pound market cap.

Poor finance has caused a very damaging decline.

Are Tim.and Co playing a very tight game with the interested parties?

Full phase 1a data is expected Q2. If we are funded to cover the end of this then no big problem.

Tim and Co should have included in the RNS on failure of drawing down these funds the amount of cash runway we have left.

This in my opinion being omitted from the RNS is appalling.

Regards and am now blowing the froth off of a couple.

Damion good evening, why do believe that 400 million is a silly comment. What do you base that on?

Are you saying that 400 million is not possible?

Phase lb is important and will give a good indication in Psoriasis.

Tim and Co very likely to have ball park figures.

Figures at end of preclinical

Figures at end of phase 1a

Figures at end of phase 1b

Or do do you believe that Tim and Co have no idea at all?

On going discussions have been going on since year dot with Sareum with interested parties.

From these informal discussions as to financial worth of SDC1801 ball park figures will be bandied about.

However, we will never be privy to these informal discussions as to who it is or how much these ball park figures are.

Take my comparison with Deucravacitinib.

4 billion up front. Later stage of course, No significant adverse effect with regards to safety and with regards to efficacy good but not outstanding with regards to PAS175 score. This was over a 16 week period and the general consensus we are looking at inhibitors that can at least equal or better the PAS175 score in a 12 week period. One or two aiming at PASI190.

Interestingly one is a Tyk2 Jak2 inhibitor!

Strange that Tyk2 should have the benefits of Tyk2 with out the adverse effects although we do know, well most of us that TYk2 interacts with Jak2.

There are later generation jak inhibitors which are way more selective than early Jak inhibitors.

There have been inhibitors with Tyk2 Jak1 jak2and Jak 3. Call it broad spectrum. They will work to an extent. They will also have off target ie adverse effects. Different diseases require differing amounts of Jak1 Jak2 Jak3 and Tyk2.

With Deucravacitinib the first Tyk2 inhibitor promising excellent safety and a mechanism ie the Allosteric route that was portrayed as the bees knees, mutts nut or dogs danglies, whatever term you like to use.

It has not been that. UC for example is better controlled with Jak1 and Jak3 in this indication.

With Jak inhibition you are looking at controlling the bodies immune system.

If it is broad based ie not overly selective it will adjust the immune system to the parts that need adjusting through whichever STAT pathway but also adjust bits they do not need adjusting with of course referred to off target effects.

There will always be good compounds , first in class compounds but never ever in a million years a compound that will treat every indication with absolute safety.

Deucravacitinib on my opinion over priced. It was deemed to have excellent safety profile, it does.

However, when recieved NDA approval for an indication and then follows commercialisation basically putting it into every conceivable auto immune condition that can starting with biggest buck market ot has not done what it says on the side of the tin so as to speak.

1801 will be very good in some Indications and not so good in others, that is the nature of the beast.

You are welcome Rebster.

Enjoy your Malt.

I had small top up at 16.11.46

Weekend off 155 mile drive home coming up and Dartford Tunnel of a Friday, A beer when l get in.

Regards

Good afternoon Rebster

From memory and l will confirm later but you had to show the a ability to raise funds when required as a condition of the CTA application.

A considerable amount would be put upfront.

Most if this would be organised by the CTO in Oz and don't forget they will be adding their fees.

However, l believe effects of food up take on compound was added and perhaps a few other odds and ends.

Will get back to you on this later.

Regards.

Sareum will still have to pay research fees. There is also health checks carried out after completion of trial for several weeks and this data needs collecting and collating. Not cheap at all.

Most likely looking around 6 weeks minimum after last dosing before we get final results.

Biomarker data will require analysis. All time consuming and costly.

Generally a phase 1 trial costs around 4 million dollars.

Regards

Ratty, you still spending the occasional night in the tarpaulin covered skip outside Sareum HQ in Pampisford?

Good to hear from you, been a few years.

Regards